Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
$INSM
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
(Zip Code)
|
|
|
(Address of principal executive offices)
|
Registrant’s telephone number, including area code: (908 ) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 7.01 —
|
Regulation FD Disclosure.
|
On August 12, 2025, Insmed Incorporated (the “Company”) issued a press release announcing that the U.S. Food and
Drug Administration (“FDA”) has approved BRINSUPRI™ (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. A copy of the press release is attached
hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The Company will host a conference call to discuss the FDA approval on August 12, 2025, at 12:00 p.m., Eastern Time, and a live webcast of the call will be available through the investor relations section of the Company’s website. A
copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.
The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such
a filing.
|
ITEM 8.01 —
|
Other Events.
|
On August 12, 2025, the Company announced that the FDA has approved BRINSUPRI (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older.
|
ITEM 9.01 —
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits
|
|
Exhibit
No.
|
Description
|
|
|
Press release issued by Insmed Incorporated on August 12, 2025.
|
||
|
Insmed Incorporated August 12, 2025 BRINSUPRI FDA Approval Presentation.
|
||
|
104
|
Cover Page Interactive Date File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Dated: August 12, 2025
|
INSMED INCORPORATED
|
|
|
By:
|
/s/ Michael A. Smith
|
|
|
Name:
|
Michael A. Smith
|
|
|
Title:
|
Chief Legal Officer and Corporate Secretary
|
|